GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

The U.K.-based company is looking to recover after a lackluster 2023.

GSK Reports Earnings Wednesday. Watch the RSV Vaccine Showdown.

McKesson

Teladoc

One of the most important sectors not only in the financial markets but also in everyone's life, is the healthcare sector. It can provide investors with good returns due to its constant growth and continuous development, and the more it grows, the more companies grow along with it.

3 Hidden Healthcare Stocks Poised for a Breakout This Year

GSK is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for GSK This Earnings Season?

We expect GSK's specialty products like Arexvy, Cabenuva, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive fourth-quarter sales performance.

GSK Gears Up for Q4 Earnings: Will It Surpass Estimates?

GSK PLC has seen its RSV vaccines shoot to blockbuster status in little over six months, according to the Financial Times citing analysts. The term blockbuster refers to any drug with annual sales of more than $1bn, a landmark likely to have been passed by Arexvy inoculation in the final quarter of last year.

GSK RSV vaccine achieves blockbuster status in just over six months

ExScientia Ltd

Pfizer

Integrating artificial intelligence and biotechnology could make 2024 a landmark year. The utilization of AI, machine learning and big data is nowadays a part of research and development (R&D) procedures in most pharmaceutical companies, positioning them well to expedite the approval of new drugs for the market.

The Cutting Edge: 3 Stocks to Buy for the Next Generation of Biotech Breakthroughs

Glaxo (GSK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GSK (GSK) Reports Next Week: Wall Street Expects Earnings Growth

SAN CARLOS, Calif.--(BUSINESS WIRE)-- #DNAinnovation--GSK has signed a collaboration & licensing agreement to leverage Elegen's cell-free DNA manufacturing tech in the dev of GSK's vaccines & medicines.

Elegen and GSK Sign Collaboration and Licensing Agreement to Further Develop Elegen's Cell-Free DNA Production Technology

GSK (GSK) closed at $39.53 in the latest trading session, marking a -0.38% move from the prior day.

GSK (GSK) Stock Dips While Market Gains: Key Facts

Haleon PLC

GSK PLC (LSE:GSK, NYSE:GSK) said it completed the sale of 300 million shares in Haleon, the consumer health giant, netting £978 million, or $1.23 billion, in the process. The sum is around $200 million shy of the cash it is handing over to take over Aiolos Bio, the respiratory and inflammatory diseases specialists.

GSK nets £978m from Haleon share sale

British drugmaker GSK said on Wednesday it had raised 978 million pounds ($1.24 billion) from a discounted stake sale in Haleon , cutting its shareholding to 4.2% in the world's largest standalone consumer healthcare firm.

GSK raises $1.24 bln from latest Haleon stake sale

GSK (GSK) closed at $39.88 in the latest trading session, marking a -0.55% move from the prior day.

GSK (GSK) Declines More Than Market: Some Information for Investors

AstraZeneca

UBS has revised its stance on two major UK-listed pharma companies - GSK PLC (LSE:GSK, NYSE:GSK) and AstraZeneca PLC (LSE:AZN) - with an upgrade for the former and a downgrade for the latter. GSK is moved from 'sell' to 'buy,' while the investment bank's call on AZ moves in the opposite direction.

GSK and AstraZeneca: A leading investment bank gives its verdict with an upgrade and a downgrade

GSK will sell a 3.2% stake, or about 300 million shares, in its spun-off consumer healthcare business Haleon , the British drugmaker said on Tuesday.

GSK to sell 3.2% stake in spin-off Haleon

Novo Nordisk

Sanofi

Drug stocks GSK, Sanofi, Merck KGaA, and Novartis look set for a good year on strong cash flows and attractive valuations, says UBS.

4 Pharma Stocks to Buy, According to an Analyst. Novo Nordisk Isn't One.

UBS analysts shook up their ratings of European drugmakers, including making a double-downgrade of AstraZeneca and a double-upgrade of U.K. rival GSK.

Sell AstraZeneca, says UBS, which upgrades European rivals including GSK

Shore Capital's recent research note on GSK PLC (LSE:GSK, NYSE:GSK) paints an optimistic picture for the pharmaceutical giant, underlining reasons for maintaining a 'Buy' recommendation with a raised fair value to 2,000p, up from 1,850p. The note points out that GSK's current market valuation, trading at a price-to-earnings ratio (PER) of approximately nine times for the financial year 2025 (FY25F), is significantly lower than its peers, averaging around 15 times.

Is GSK worth £20 a share? This broker seems to thinks so

Deutsche Bank

GSK has received a healthy price target upgrade from analysts at Deutsche Bank, which has the UK pharma as a top pick in a sector with a mixed outlook in 2024. “Top-down, our sector view remains neutral and perhaps even more incrementally cautious for 2023 relative to FY23; however we do have a very clear rank order of preferences, with Novo, GSK and Novartis our buy recommendations.

GSK still a top pick in pharma sector for Deutsche Bank

GSK's proposed acquisition of Aiolos is set to add the latter's long-acting anti-TSLP monoclonal antibody, AIO-001, to GSK's broad portfolio of respiratory products.

GSK to Buy Private Biotech, Strengthen Respiratory Pipeline

Agenus

Bristol-Myers

Compugen

iTeos Therapeutics, Inc.

Merck

Novartis

Arcus Biosciences

iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

GSK plc (GSK) 42nd Annual JP Morgan Healthcare Conference (Transcript)

British pharmaceutical giant GSK PLC on Tuesday announced a $1.4 billion deal to acquire Aiolos Bio Inc., boosting its respiratory portfolio.

GSK Boosts Respiratory Portfolio with $1.4 Billion Aiolos Bio Acquisition

GSK PLC (LSE:GSK, NYSE:GSK) should deliver better than expected fourth-quarter results on January 31, according to Barclays, amid heightened expectations driven by the robust performance of its RSV vaccine, Arexvy. Analysts at the bank, who also wondered if 2024 could be "the year Zantac goes away?

GSK strong finish expected, says Barclays

SAN FRANCISCO & LONDON--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and Aiolos Bio, Inc. (Aiolos) today announced that they have entered into an agreement under which GSK will acquire Aiolos, a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with certain respiratory and inflammatory conditions, for a $1 billion upfront payment and up to $400 million in certain success-based regulatory milestone payments. The acquisition provides GSK with access.

GSK Enters Agreement to Acquire Aiolos Bio

GSK on Tuesday said it had struck a deal to acquire asthma drug developer Aiolos Bio for up to $1.4 billion, as the British pharmaceutical giant pushes forward with plans to bolster its development pipeline by snapping up autoimmune and respiratory focused biotech companies.

News for GlaxoSmithKline Stock (GSK)